CVM vs. ADAP, IPSC, MGX, ZURA, IPHA, CADL, IVVD, GNFT, CHRS, and CGEN
Should you be buying CEL-SCI stock or one of its competitors? The main competitors of CEL-SCI include Adaptimmune Therapeutics (ADAP), Century Therapeutics (IPSC), Metagenomi (MGX), Zura Bio (ZURA), Innate Pharma (IPHA), Candel Therapeutics (CADL), Invivyd (IVVD), Genfit (GNFT), Coherus BioSciences (CHRS), and Compugen (CGEN). These companies are all part of the "biological products, except diagnostic" industry.
Adaptimmune Therapeutics (NASDAQ:ADAP) and CEL-SCI (NYSE:CVM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.
Adaptimmune Therapeutics has a beta of 2.44, indicating that its stock price is 144% more volatile than the S&P 500. Comparatively, CEL-SCI has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500.
In the previous week, Adaptimmune Therapeutics had 4 more articles in the media than CEL-SCI. MarketBeat recorded 4 mentions for Adaptimmune Therapeutics and 0 mentions for CEL-SCI. CEL-SCI's average media sentiment score of 0.94 beat Adaptimmune Therapeutics' score of 0.00 indicating that Adaptimmune Therapeutics is being referred to more favorably in the media.
Adaptimmune Therapeutics currently has a consensus target price of $2.67, suggesting a potential upside of 164.03%. Given CEL-SCI's higher possible upside, research analysts clearly believe Adaptimmune Therapeutics is more favorable than CEL-SCI.
Adaptimmune Therapeutics received 308 more outperform votes than CEL-SCI when rated by MarketBeat users. Likewise, 62.47% of users gave Adaptimmune Therapeutics an outperform vote while only 0.00% of users gave CEL-SCI an outperform vote.
CEL-SCI has lower revenue, but higher earnings than Adaptimmune Therapeutics. CEL-SCI is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.
CEL-SCI has a net margin of 0.00% compared to CEL-SCI's net margin of -890.13%. Adaptimmune Therapeutics' return on equity of -218.00% beat CEL-SCI's return on equity.
31.4% of Adaptimmune Therapeutics shares are held by institutional investors. Comparatively, 12.1% of CEL-SCI shares are held by institutional investors. 12.4% of Adaptimmune Therapeutics shares are held by insiders. Comparatively, 14.1% of CEL-SCI shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Adaptimmune Therapeutics beats CEL-SCI on 11 of the 16 factors compared between the two stocks.
Get CEL-SCI News Delivered to You Automatically
Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
